Roche reports further accelerated sales growth in third quarter, Roche

Release Date: 2009-10-15

Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs). Both divisions grow significantly faster than their respective markets. Genentech integration progressing successfully.
Commenting on the Group’s nine-month sales figures, Roche CEO Severin Schwan said: "The Roche Group continued to perform very strongly in the third quarter. Sales by both the Pharmaceuticals and Diagnostics divisions are significantly outgrowing their respective markets. Based on this performance, we expect another very good full-year result. I’m particularly pleased with the excellent progress we’re making in joining forces with Genentech. The new leadership structure we announced recently will ensure that we continue to translate excellent science into innovative medicines for patients."
Type: NORMAL
Company: Roche
Country: Switzerland
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.